In this activity, Dr. Beth Faiman covers how to manage lenalidomide-related diarrhea in newly diagnosed patients with multiple myeloma.

In this activity, Dr. Faiman will review the results of a phase I/II study of azacitidine in combination with lenalidomide and dexamethasone in patients with RRMM.

Join Dr. Faiman as she discusses the results from evaluating the safety and efficacy of pomalidomide in the real-world setting with RRMM patients.

In this activity, Dr. Drake provides some key updates in the management of bone disease in mutliple myeloma over that past couple years.

Join Dr. Drake as he covers the risk of developing complications in the skeleton after a patient with multiple myeloma achieves complete remission.

Join Dr. Philip McCarthy as he explains the development of central nervous system toxicity after cytokine-release syndrome (CRS), and also whether CRS affects CAR T cells.

In this activity, Dr. Philip McCarthy discusses cytokine-release syndrome and the most common treatment approaches.

Dr. Holstein explains the risk of developing an SPM on lenalidomide maintenance vs. the benefit of maintenance in delaying progression or death from myeloma, and how to counsel patients.

Dr. Holstein reviews the impact maintenance therapy has on patient outcomes, and what factors you must consider when prescribing maintenance therapy.

Dr. Richardson provides a brief update on recent developments in CAR-T therapy in patients with multiple myeloma, and what we can see on the horizon.